{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:27:32Z","timestamp":1787041652090,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119113","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:07:50Z","timestamp":1782850070000},"page":"119113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["NCP07: A potent ER\u03b1 CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer"],"prefix":"10.1016","volume":"317","author":[{"given":"Jinsen","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bing","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chune","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8498-063X","authenticated-orcid":false,"given":"Hai-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119113_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119113_bib2","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41586-025-09812-3","article-title":"Whole-genome landscapes of 1,364 breast cancers","volume":"649","author":"Kim","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119113_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2026.119113_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1639","article-title":"Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients","volume":"9","author":"Dunnwald","year":"2007","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119113_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-med-052423-122001","article-title":"New oral selective estrogen receptor degraders redefine management of estrogen receptor-positive breast cancer","volume":"76","author":"Pathak","year":"2025","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2026.119113_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102825","article-title":"Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review","volume":"130","author":"Gheysen","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.119113_bib7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"Ebctcg, 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119113_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119113_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119113_bib10","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1021\/acs.jmedchem.3c00136","article-title":"Targeting the estrogen receptor for the treatment of breast cancer: recent advances and challenges","volume":"66","author":"Rej","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib11","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41588-025-02187-1","article-title":"APOBEC3 mutagenesis drives therapy resistance in breast cancer","volume":"57","author":"Gupta","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.119113_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119113_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119113_bib14","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/onc.2016.382","article-title":"Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer","volume":"36","author":"Harrod","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119113_bib15","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119113_bib16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37161","article-title":"The SERM\/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells","volume":"7","author":"Fanning","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.119113_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41568-018-0001-z","article-title":"Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance","volume":"18","author":"Katzenellenbogen","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119113_bib18","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1158\/1078-0432.CCR-19-1129","article-title":"Early enrichment of ESR1 mutations and the impact on gene expression in presurgical primary breast cancer treated with aromatase inhibitors","volume":"25","author":"Leal","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119113_bib19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","article-title":"Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive cancer centres' ALERT group. Assessment of liver and endometrial cancer risk following tamoxifen","volume":"356","author":"Bergman","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119113_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/carcin\/22.6.839","article-title":"Understanding the genotoxicity of tamoxifen?","volume":"22","author":"Phillips","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2026.119113_bib21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1742-1241.2007.01587.x","article-title":"The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer","volume":"61","author":"Fabian","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.119113_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.7-6-477","article-title":"FDA drug approval summaries: fulvestrant","volume":"7","author":"Bross","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.119113_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","article-title":"Targeted protein degrader development for cancer: advances, challenges, and opportunities","volume":"44","author":"Fang","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119113_bib24","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.1039\/D2CS00117A","article-title":"SERDs: a case study in targeted protein degradation","volume":"51","author":"Wang","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119113_bib25","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2147\/DDDT.S380925","article-title":"Oral selective estrogen receptor degraders (SERDs) in breast cancer: advances, challenges, and current status","volume":"16","author":"Downton","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejmech.2026.119113_bib26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-023-01861-0","article-title":"Elacestrant: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119113_bib27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40265-025-02266-x","article-title":"Imlunestrant: first approval","volume":"86","author":"Keam","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119113_bib28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without Abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119113_bib29","doi-asserted-by":"crossref","first-page":"15094","DOI":"10.1021\/acs.jmedchem.0c00913","article-title":"Selective estrogen receptor degraders (SERDs): a promising strategy for estrogen receptor positive endocrine-resistant breast cancer","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.cell.2019.06.026","article-title":"Therapeutic ligands antagonize estrogen receptor function by impairing its mobility","volume":"178","author":"Guan","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119113_bib31","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O'Leary","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119113_bib32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/2159-8290.CD-22-1387","article-title":"ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1-Mutant breast cancer","volume":"14","author":"Kingston","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119113_bib33","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119113_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112689","article-title":"Targeting estrogen receptor alpha for degradation with PROTACs: a promising approach to overcome endocrine resistance","volume":"206","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11523-025-01137-5","article-title":"PROteolysis TArgeting chimera (PROTAC) estrogen receptor degraders for treatment of estrogen receptor-positive advanced breast cancer","volume":"20","author":"Hamilton","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ejmech.2026.119113_bib36","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119113_bib38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2026.119113_bib39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"Abstract 44: the discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119113_bib40","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119113_bib41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119113_bib42","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of Estrogen Receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib43","doi-asserted-by":"crossref","first-page":"12559","DOI":"10.1021\/acs.jmedchem.3c01186","article-title":"Discovery of ERD-3111 as a potent and orally efficacious estrogen receptor PROTAC degrader with strong antitumor activity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib44","doi-asserted-by":"crossref","first-page":"20933","DOI":"10.1021\/acs.jmedchem.4c01401","article-title":"Discovery of ERD-12310A as an exceptionally potent and orally efficacious PROTAC degrader of estrogen receptor \u03b1 (ER\u03b1)","volume":"67","author":"Rej","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib45","doi-asserted-by":"crossref","first-page":"19010","DOI":"10.1021\/acs.jmedchem.4c01521","article-title":"Discovery of ERD-1233 as a potent and orally efficacious estrogen receptor PROTAC degrader for the treatment of ER+ human breast cancer","volume":"67","author":"Acharyya","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib46","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1021\/acs.jmedchem.2c02032","article-title":"Discovery of a novel class of PROTACs as potent and selective estrogen receptor \u03b1 degraders to overcome endocrine-resistant breast cancer","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen carcinogenesis in breast cancer","volume":"354","author":"Yager","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119113_bib48","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.molcel.2017.07.026","article-title":"Structural and functional impacts of ER coactivator sequential recruitment","volume":"67","author":"Yi","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119113_bib49","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.molcel.2020.06.031","article-title":"Structural insights of transcriptionally active, full-length androgen receptor coactivator complexes","volume":"79","author":"Yu","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119113_bib50","first-page":"357","article-title":"ERalpha dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER(+) breast cancer, Nat","volume":"6","author":"Liang","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119113_bib51","doi-asserted-by":"crossref","first-page":"13640","DOI":"10.1021\/acs.jmedchem.5c00495","article-title":"Targeted degradation of the estrogen receptor \u03b1 through unconventional coactivator binding site (CBS)","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib52","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26857","article-title":"Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers","volume":"6","author":"Raj","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.119113_bib53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13058-019-1227-8","article-title":"Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4\/6 inhibitors against estrogen receptor-positive breast cancers","volume":"21","author":"Viswanadhapalli","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119113_bib54","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0092-8674(00)81401-4","article-title":"ARF promotes MDM2 degradation and stabilizes p53: locus deletion impairs both the Rb and p53 tumor suppression pathways","volume":"92","author":"Zhang","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119113_bib55","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41418-021-00890-0","article-title":"CRL2-KLHDC3 E3 ubiquitin ligase complex suppresses ferroptosis through promoting p14 degradation","volume":"29","author":"Zhang","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119113_bib56","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/nar\/gkv047","article-title":"Regulation of mammalian nucleotide metabolism and biosynthesis","volume":"43","author":"Lane","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119113_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116572","article-title":"Novel Hsp90-Targeting PROTACs: enhanced synergy with cisplatin in combination therapy of cervical cancer","volume":"275","author":"Liang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119113_bib58","doi-asserted-by":"crossref","first-page":"11516","DOI":"10.1021\/acs.jmedchem.5c00425","article-title":"Intercepting the downstream of the estrogen receptor signaling pathway: discovery of a potent and efficient SRC-3 PROTAC degrader for overcoming endocrine resistance breast cancer","volume":"68","author":"Liang","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:02:13Z","timestamp":1787040133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":58,"alternative-id":["S0223523426005581"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119113","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NCP07: A potent ER\u03b1 CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119113"}}